Quick-Med and Avery Dennison Enter Into Joint Development Agreement
Companies to Pursue Development of NIMBUS®
Antimicrobial Technology for Adhesives to Combat Infections
Will Bring Highly Effective, Non-Leaching, and Affordable Barrier
Protection to the Multi-Billion Global Medical Adhesives Market
Gainesville, Florida – April 23, 2009 – Quick-Med Technologies, Inc. (OTCBB:
QMDT) and Avery Dennison Corporation (NYSE: AVY) announced today that they
entered into a joint development and exclusive option agreement to collaborate in
applying Quick-Med’s proprietary NIMBUS® technology to adhesives for medical device
and industrial applications.
“We are excited to team with Avery Dennison Corporation to incorporate our advanced
NIMBUS technology in adhesives,” said J. Ladd Greeno, CEO of Quick-Med
Technologies. “Avery Dennison is the respected leader in developing advanced adhesives
to meet the requirements of medical device manufacturers. This collaboration will
leverage NIMBUS technology to a next generation of antimicrobial adhesives to address
growing infection concerns.”
“Our partnership with Quick-Med will enable us to bring innovative, next-generation
antimicrobial technology to meet the needs of both existing and potential customers,”
said Kevin Young, Vice President & General Manager of Avery Dennison Corporation.
“NIMBUS technology will continue Avery Dennison innovation firsts by bringing much
needed, uniquely effective and affordable, non-leaching antimicrobial protection to
applications for the medical devices market.”
What makes NIMBUS different from other antimicrobial technology is its permanent
bond and its ability to be effective even in the presence of large amounts of serum and
body fluids. The active agent is permanently bonded to the substrate, keeping the biocide
from depletion or leaching antimicrobials into the wound, while killing microbes (such as
MRSA, VRE, and many others) that are present on the device. Being bound to the
substrate keeps the antimicrobial at full strength; test results show that even in 90%
serum, NIMBUS continues to kill microbes outperforming other antimicrobials.
About NIMBUS®
NIMBUS is a next-generation antimicrobial technology that is non-leaching, non-toxic,
long-lasting and not blocked by organics such as blood, urine and perspiration. According
to Gregory Schultz, Professor, Institute for Wound Research at the University of Florida
and Past President of the Wound Healing Society, “NIMBUS poses no danger of bacteria
developing resistance, or of releasing toxic material into the wound and impeding the
wound healing process. It is a novel technology: bonded and effective even in high
concentrations of body fluids.”
About Avery Dennison Corporation
Avery Dennison is a recognized industry leader that develops innovative identification
and decorative solutions for businesses and consumers worldwide. The Company’s
products include pressure-sensitive labeling materials; graphics imaging media; retail
apparel ticketing and branding systems; RFID inlays and tags; office products; specialty
tapes; and a variety of specialized labels for automotive, industrial and durable goods
applications. A FORTUNE 500 Company with sales of $6.7 billion in 2008, Avery
Dennison is based in Pasadena, California and employs more than 36,000 employees in
over 60 countries. For more information, visit www.averydennison.com.
|
